English
Применение апиксабана у пожилых пациентов с фибрилляцией предсердий
DOI: https://dx.doi.org/10.18565/therapy.2024.10.97-106
А.Р. Касимова, А.М. Борисов
1) ФГБОУ ВО «Первый Санкт-Петербургский государственный университет им. академика И.П. Павлова» Минздрава России; 2) ФГБУ «Национальный медицинский исследовательский центр травматологии и ортопедии им. Р.Р. Вредена» Минздрава России, г. Санкт-Петербург
Цель обзора – на основании литературных данных проанализировать особенности применения различных лекарственных средств из группы ПОАК у пациентов пожилого возраста с ФП.
Результаты. Эффективность применения антикоагулянтов у пациентов с ФП не вызывает сомнений. В большом количестве исследований показана их эффективность как для первичной (до первого сердечно-сосудистого события), так и вторичной тромбопрофилактики. Для пожилых пациентов существует большое количество факторов, которые необходимо учитывать врачу при выборе оптимальной стратегии тромбопрофилактики: общий замедленный метаболизм, повышенный риск кровотечений, полиморбидность и полипрагмазия.
Заключение. Исследования последнего времени демонстрируют эффективность апиксабана в предупреждении ишемических инсультов и других тромботических событий, превышающую или не уступающую таковой у давно применяемого варфарина. В обзоре освещены основные особенности применения различных ПОАК у пожилых пациентов с ФП, что дает практикующему врачу рабочие инструменты для рационального выбора фармакотерапии.
Литература
1. Sagris M., Vardas E.P., Theofilis P. et al. Atrial fibrillation: Pathogenesis, predisposing factors, and genetics. Int J Mol Sci. 2021; 23(1): 6. https://doi.org/10.3390/ijms23010006. PMID: 35008432. PMCID: PMC8744894. 2. Staerk L., Sherer J.A., Ko D. et al. Atrial fibrillation: Epidemiology, pathophysiology, and clinical outcomes. Circ Res. 2017; 120(9): 1501–17. https://doi.org/10.1161/circresaha.117.309732. PMID: 28450367. PMCID: PMC5500874. 3. Lane D.A., Skjøth F., Lip G.Y.H. et al. Temporal trends in incidence, prevalence, and mortality of atrial fibrillation in primary care. J Am Heart Assoc. 2017; 6(5): e005155. https://doi.org/10.1161/jaha.116.005155. PMID: 28455344. PMCID: PMC5524079. 4. Morin D.P., Bernard M.L., Madias C. et al. The state of the art: Atrial fibrillation epidemiology, prevention, and treatment. Mayo Clin Proc. 2016; 91(12): 1778–1810. https://doi.org/10.1016/j.mayocp.2016.08.022. PMID: 27825618. 5. Patel P., Patel S.H., Siddegowda A. et al. Effectiveness of novel oral anticoagulants versus warfarin in patients with atrial fibrillation: A systematic review and meta-analysis. Cureus. 2024; 16(5): e61374. https://doi.org/10.7759/cureus.61374. PMID: 38947715. PMCID: PMC11214541. 6. Trevisan M., Hjemdahl P., Clase C.M. et al. Cardiorenal outcomes among patients with atrial fibrillation treated with oral anticoagulants. Am J Kidney Dis. 2023; 81(3): 307–317.e1. https://doi.org/10.1053/j.ajkd.2022.07.017. PMID: 36208798. 7. Goette A., Kalman J.M., Aguinaga L. et al. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication. Europace. 2016; 18(10): 1455–90. https://doi.org/10.1093/europace/euw161. PMID: 27402624. PMCID: PMC6392440. 8. Healey J.S., Connolly S.J., Gold M.R. et al.; ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012; 366(2): 120–29. https://doi.org/10.1056/nejmoa1105575. PMID: 22236222. 9. Deng H., Bai Y., Shantsila A. et al. Clinical scores for outcomes of rhythm control or arrhythmia progression in patients with atrial fibrillation: A systematic review. Clin Res Cardiol. 2017; 106(10): 813–23. https://doi.org/10.1007/s00392-017-1123-0. PMID: 28560516. PMCID: PMC5613037. 10. Chao T.-F., Liu C.-J., Lin Y.-J. et al. Oral anticoagulation in very elderly patients with atrial fibrillation: A nationwide cohort study. Circulation. 2018; 138(1): 37–47. https://doi.org/10.1161/circulationaha.117.031658. PMID: 29490992. 11. Silverio A., Di Maio M., Prota C. et al. Safety and efficacy of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: Systematic review and meta-analysis of 22 studies and 440 281 patients. Eur Heart J Cardiovasc Pharmacother. 2021; 7(FI1): f20–f29. https://doi.org/10.1093/ehjcvp/pvz073. PMID: 31830264. 12. Shen N.-N., Wu Y., Wang N. et al. Direct oral anticoagulants vs. vitamin-K antagonists in the elderly with atrial fibrillation: A systematic review comparing benefits and harms between observational studies and randomized controlled trials. Front Cardiovasc Med. 2020; 7: 132. https://doi.org/10.3389/fcvm.2020.00132. PMID: 33134323. PMCID: PMC7511536. 13. Lawal O.D., Aronow H.D., Shobayo F. et al. Comparative effectiveness and safety of direct oral anticoagulants and warfarin in patients with atrial fibrillation and chronic liver disease: A nationwide cohort study. Circulation. 2023; 147(10): 782–94. https://doi.org/10.1161/circulationaha.122.060687. PMID: 36762560. 14. Fong K.Y., Chan Y.H., Wang Y. et al. Dementia risk of direct oral anticoagulants versus warfarin for atrial fibrillation: Systematic review and meta-analysis. JACC Asia. 2023; 3(5): 776–86. https://doi.org/10.1016/j.jacasi.2023.07.012. PMID: 38095004. PMCID: PMC10715893. 15. Steffel J., Collins R., Antz M. et al. 2021 European Heart Rhythm Association Practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021; 23(10): 1612–76. https://doi.org/10.1093/europace/euab065. PMID: 33895845. 16. Andreotti F., Geisler T., Collet J.-P. et al. Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 update by the ESC Working Group on Thrombosis. Eur Heart J. 2023; 44(4): 262–79. https://doi.org/10.1093/eurheartj/ehac515. PMID: 36477865. 17. Lip G.Y.H., Nieuwlaat R., Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation. Chest. 2010; 137(2): 263–72. https://doi.org/10.1378/chest.09-1584. PMID: 19762550. 18. Pisters R., Lane D.A., Nieuwlaat R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest. 2010; 138(5): 1093–1100. https://doi.org/10.1378/chest.10-0134. PMID: 20299623. 19. Hijazi Z., Lindbäck J., Alexander J.H. et al.; ARISTOTLE and STABILITY Investigators. The ABC (age, biomarkers, clinical history) stroke risk score: A biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J. 2016; 37(20): 1582–90. https://doi.org/10.1093/eurheartj/ehw054. PMID: 26920728. PMCID: PMC4875560. 20. Costa F., van Klaveren D., James S. et al.; PRECISE-DAPT Study Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: A pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017; 389(10073): 1025–34. https://doi.org/10.1016/s0140-6736(17)30397-5. PMID: 28290994. 21. Urban P., Mehran R., Colleran R. et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: A consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019; 40(31): 2632–53. https://doi.org/10.1093/eurheartj/ehz372. PMID: 31116395. PMCID: PMC6736433. 22. Olesen J.B., Lip G.Y.H., Kamper A.-L. et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012; 367(7): 625–35. https://doi.org/10.1056/nejmoa1105594. PMID: 22894575. 23. Patel M.R., Mahaffey K.W., Garg J. et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10): 883–91. https://doi.org/10.1056/nejmoa1009638. PMID: 21830957. 24. Connolly S.J., Ezekowitz M.D., Yusuf S. et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12): 1139–51. https://doi.org/10.1056/nejmoa0905561. PMID: 19717844. 25. Murtaza G., Turagam M.K., Garg J. et al. Safety and efficacy of apixaban versus warfarin in patients with atrial fibrillation orvenous thromboembolism and end-stage renal disease on hemodialysis: A systematic review and meta-analysis. Indian Pacing Electrophysiol J. 2021; 21(4): 221–26. https://doi.org/10.1016/j.ipej.2021.04.002. PMID: 33866017. PMCID: PMC8263313. 26. Giugliano R.P., Ruff C.T., Braunwald E. et al.; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369(22): 2093–2104. https://doi.org/10.1056/nejmoa1310907. PMID: 24251359. 27. Hijazi Z., Hohnloser S.H., Oldgren J. et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation. 2014; 129(9): 961–70. https://doi.org/10.1161/circulationaha.113.003628. PMID: 24323795. 28. Hohnloser S.H., Hijazi Z., Thomas L. et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: Insights from the ARISTOTLE trial. Eur Heart J. 2012; 33(22): 2821–30. https://doi.org/10.1093/eurheartj/ehs274. PMID: 22933567. 29. Bohula E.A., Giugliano R.P., Ruff C.T. et al. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation. 2016; 134(1): 24–36. https://doi.org/10.1161/circulationaha.116.022361. PMID: 27358434. 30. Harel Z., Sholzberg M., Shah P.S. et al. Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD. J Am Soc Nephrol. 2014; 25(3): 431–42. https://doi.org/10.1681/asn.2013040361. PMID: 24385595. PMCID: PMC3935586. 31. Parker K., Hartemink J., Saha A. et al. A systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney disease. J Nephrol. 2022; 35(8): 2015–33. https://doi.org/10.1007/s40620-022-01413-x. PMID: 36006608. PMCID: PMC9584987. 32. Rhee T.-M., Lee S.-R., Choi E.-K. et al. Efficacy and safety of oral anticoagulants for atrial fibrillation patients with chronic kidney disease: A systematic review and meta-analysis. Front Cardiovasc Med. 2022; 9: 885548. https://doi.org/10.3389/fcvm.2022.885548. PMID: 35757349. PMCID: PMC9226375. 33. Reinecke H., Engelbertz C., Bauersachs R. et al. A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: The AXADIA-AFNET 8 study. Circulation. 2023; 147(4): 296–309. https://doi.org/10.1161/circulationaha.122.062779. PMID: 36335915. PMCID: PMC9875840. 34. Pokorney S.D., Chertow G.M., Al-Khalidi H.R. et al. Apixaban for patients with atrial fibrillation on hemodialysis: A multicenter randomized controlled trial. Circulation. 2022; 146(23): 1735–45. https://doi.org/10.1161/circulationaha.121.054990. PMID: 36335914. 35. Hsu C.-C., Chen C.-C., Chou C.-Y. et al. Effectiveness and safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and advanced kidney disease. J Thromb Thrombolysis. 2023; 56(4): 518–28. https://doi.org/10.1007/s11239-023-02859-x. PMID: 37452906. PMCID: PMC10550875. 36. Harrington J., Carnicelli A.P., Hua K. et al. Direct oral anticoagulants versus warfarin across the spectrum of kidney function: Patient-level network meta-analyses from COMBINE AF. Circulation. 2023; 147(23): 1748–57. https://doi.org/10.1161/circulationaha.122.062752. PMID: 37042255. PMCID: PMC10309661. 37. AlTurki A., Marafi M., Dawas A. et al. Meta-analysis evaluating apixaban in patients with atrial fibrillation and end-stage renal disease requiring dialysis. J Arrhythm. 2024; 40(3): 440–47. https://doi.org/10.1002/joa3.13051. PMID: 38939758. PMCID: PMC11199838. 38. Adelakun A.R., Turgeon R.D., De Vera M.A. et al. Oral anticoagulant switching in patients with atrial fibrillation: A scoping review. BMJ open. 2023; 13(4): e071907. https://doi.org/10.1136/bmjopen-2023-071907. PMID: 37185198. PMCID: PMC10151984. 39. Varghese D., Ishida C., Patel P., Koya H.H. Polypharmacy. StatPearls. Treasure Island (FL): StatPearls Publishing. 2024. PMID: 30422548. 40. Focks J.J., Brouwer M.A., Wojdyla D.M. et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: Post hoc analysis of the ARISTOTLE trial. BMJ. 2016: 353: i2868. https://doi.org/10.1136/bmj.i2868. PMID: 27306620. PMCID: PMC4908974. 41. Piccini J.P., Hellkamp A.S., Washam J.B. et al. Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. Circulation. 2016; 133(4): 352–60. https://doi.org/10.1161/circulationaha.115.018544. PMID: 26673560. 42. Hodin S., Basset T., Jacqueroux E. In vitro comparison of the role of P-glycoprotein and breast cancer resistance protein on direct oral anticoagulants disposition. Eur J Drug Metab Pharmacokinet. 2018; 43(2): 183–91. https://doi.org/10.1007/s13318-017-0434-x. PMID: 28895074. 43. Jungbauer L., Dobias C., Stöllberger C., Weidinger F. The frequency of prescription of P-glycoprotein-affecting drugs in atrial fibrillation. J Thromb Haemost. 2010; 8(9): 2069–70. https://doi.org/10.1111/j.1538-7836.2010.03943.x. PMID: 20553377. 44. Kim D.H., Pawar A., Gagne J.J. et al. Frailty and clinical outcomes of direct oral anticoagulants versus warfarin in older adults with atrial fibrillation: A cohort study. Ann Intern Med. 2021; 174(9): 1214–23. https://doi.org/10.7326/m20-7141. PMID: 34280330. PMCID: PMC8453126. 45. Grymonprez M., Vanspranghe K., Capiau A. et al. Impact of P-glycoprotein and/or CYP3A4-interacting drugs on effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: A meta-analysis. Br J Clin Pharmacol. 2022; 88(7): 3039–51. https://doi.org/10.1111/bcp.15265. PMID: 35132677. 46. Gronich N., Stein N., Muszkat M. Association between use of pharmacokinetic-interacting drugs and effectiveness and safety of direct acting oral anticoagulants: Nested case-control study. Clin Pharmacol Ther. 2021; 110(6): 1526–36. https://doi.org/10.1002/cpt.2369. PMID: 34287842. PMCID: PMC9290518. 47. Hill K., Sucha E., Rhodes E. et al. Risk of hospitalization with hemorrhage among older adults taking clarithromycin vs azithromycin and direct oral anticoagulants. JAMA Intern Med. 2020; 180(8): 1052–60. https://doi.org/10.1001/jamainternmed.2020.1835. PMID: 32511684. PMCID: PMC7281381. 48. Ramagopalan S.V., Graham S., Carroll R. et al. Discontinuation and primary care visits in nonvalvular atrial fibrillation patients treated with apixaban or warfarin. J Comp Eff Res. 2019; 8(6): 371–79. https://doi.org/10.2217/cer-2019-0005. PMID: 30734571. 49. Xie X., Liu Y., Li J. et al. Fracture risks in patients with atrial fibrillation treated with different oral anticoagulants: A meta-analysis and systematic review. Age Ageing. 2022; 51(1): afab264. https://doi.org/10.1093/ageing/afab264. PMID: 35077554. PMCID: PMC8789302. 50. Simon T.G., Schneeweiss S., Singer D.E. et al. Prescribing trends of oral anticoagulants in US patients with cirrhosis and nonvalvular atrial fibrillation. J Am Heart Assoc. 2023; 12(3): e026863. https://doi.org/10.1161/jaha.122.026863. PMID: 36625307. PMCID: PMC9973619.
Об авторах / Для корреспонденции
Алина Рашидовна Касимова, к. м. н., доцент, доцент кафедры клинической фармакологии и доказательной медицины ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. академика И.П. Павлова» Минздрава России, врач – клинический фармаколог отделения клинической фармакологии ФГБУ «Национальный медицинский исследовательский центр травматологии и ортопедии им. Р.Р. Вредена» Минздрава России. Адрес: 197022, г. Санкт-Петербург, ул. Льва Толстого, д. 6–8.
E-mail: kasi-alina@yandex.ru
ORCID: https://orcid.org/0000-0001-6284-7133. eLibrary SPIN: 3131-4385
Алексей Михайлович Борисов, врач – клинический фармаколог отделения клинической фармакологии ФГБУ «Национальный медицинский исследовательский центр травматологии и ортопедии им. Р.Р. Вредена» Минздрава России. Адрес: 195427, г. Санкт-Петербург, ул. Байкова, д. 8.
E-mail: amborisov@rniito.ru
ORCID: https://orcid.org/0000-0003-3449-8196. eLibrary SPIN: 2928-4410
Похожие статьи
